Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session

80TiP - High-dose aumolertinib versus osimertinib in EGFR T790M+ NSCLC patients with brain metastases (ATTACK)


31 Mar 2023


Poster Display session


Shun Lu


Journal of Thoracic Oncology (2023) 18 (4S): S35-S88.


S. Lu1, L. Han2, D. Lv3, Z. Zhang4, J. Wu5, Q. Wang6, X. Dong7, Y. Hu8, J. Chen9, L. Wu10

Author affiliations

  • 1 Shanghai/CN
  • 2 Xuzhou Central Hospital/The Fourth People's Hospital of Xuzhou, Xuzhou/CN
  • 3 Affiliated Taizhou Hospital of Zhejiang Province of Wenzhou Medical University, 318000 - Taizhou/CN
  • 4 Anhui Provincial Cancer Hospital, Hefei/CN
  • 5 The First Affiliated Hospital of Hainan Medical College, Haikou/CN
  • 6 Henan Cancer Hospital/Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou/CN
  • 7 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology/ Cancer Center Union Hospital, Wuhan/CN
  • 8 Hubei Cancer Hospital, Wuhan/CN
  • 9 Hunan Provincial Cancer Hospital, Changsha/CN
  • 10 Hunan Cancer Hospital, Changsha/CN


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 80TiP


Third-generation EGFR-TKIs have demonstrated superior CNS efficacy compared with first-generation EGFR-TKIs or chemotherapy in previous phase III studies (AENEAS, FLAURA, AURA3). However, there is a lack of head-to-head comparison of CNS efficacy between third-generation EGFR-TKIs. Herein, we conduct the ATTACK study to evaluate the efficacy and safety of aumolertinib compared with osimertinib in EGFR T790M+ NSCLC patients with brain metastases.

Trial design

ATTACK is a multicenter, open-label, randomized, controlled trial. Patients with histologic or cytologic confirmation of advanced NSCLC and are known to have progression of radiologic disease on first- or second-generation EGFR-TKIs and harbor an EGFR T790M mutation are eligible. At baseline, patients are required to have at least one measurable intracranial lesion, defined as ≥10 mm. Approximately 232 patients will be randomized (1:1) to receive either 165 mg aumolertinib or 80 mg osimertinib, administered once daily orally, stratified by the type of EGFR mutation (Ex19del or L858R). Treatment continues in 21-day cycles until disease progression, withdrawal of consent, the development of unacceptable side effects, or the fulfillment of other discontinuation criteria. The primary endpoint is intracranial progression free survival (iPFS). Secondary endpoints include PFS, objective response rate (ORR), disease control rate (DCR), intracranial ORR (iORR), intracranial DCR (iDCR), overall survival (OS), and safety. Adverse effects are graded per CTCAE v.5.0. The first patient had been enrolled in November 2022.

Clinical trial identification


Legal entity responsible for the study

Shanghai Chest Hospital.


Jiangsu Hansoh Pharmaceutical Group Co., Ltd.


S. Lu: Financial Interests, Personal, Advisory Role: AstraZeneca, Pfizer, Boehringer Ingelheim, Hutchison MediPharma, Simcere Pharmaceutical Group, Zai Lab, GenomiCare, Yuhan, Prime Oncology, Roche; Financial Interests, Personal, Invited Speaker: AstraZeneca, Roche, Hansoh Pharma, Hengrui Therapeutics; Financial Interests, Personal, Research Grant: AstraZeneca (Inst), Hutchison MediPharma (Inst), BMS (Inst), Hengrui Therapeutics (Inst), BeiGene (Inst), Roche (Inst). All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.